摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[5-Amino-1-(5-O-phosphonopentofuranosyl)-1H-imidazole-4-carbonyl]aspartic acid

中文名称
——
中文别名
——
英文名称
N-[5-Amino-1-(5-O-phosphonopentofuranosyl)-1H-imidazole-4-carbonyl]aspartic acid
英文别名
2-[[5-amino-1-[3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]imidazole-4-carbonyl]amino]butanedioic acid
N-[5-Amino-1-(5-O-phosphonopentofuranosyl)-1H-imidazole-4-carbonyl]aspartic acid化学式
CAS
——
化学式
C13H19N4O12P
mdl
——
分子量
454.28
InChiKey
NAQGHJTUZRHGAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -4.3
  • 重原子数:
    30
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    264
  • 氢给体数:
    8
  • 氢受体数:
    14

文献信息

  • [EN] OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'OXAZOLE DESTINÉS ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
    申请人:LIFEARC
    公开号:WO2018122550A1
    公开(公告)日:2018-07-05
    A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: • B is an aryl or heteroaryl group optionally substituted by one or more R10 groups; and * X is selected from 0, (CR11 R12 ) p and (CR11 R12 ) p CO. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).
    该发明的第一个方面涉及式(I)的化合物,或其药学上可接受的盐或酯,其中:• B是芳基或杂芳基,可选择地由一个或多个R10基团取代;和* X从0,(CR11 R12) p和(CR11 R12) p CO中选择。所述化合物能够抑制PAICS,并且在治疗增生性疾病方面是有用的。进一步的方面涉及制药组合物、治疗用途和制备式(I)化合物的过程。
  • [EN] OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'OXAZOLE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
    申请人:LIFEARC
    公开号:WO2018122549A1
    公开(公告)日:2018-07-05
    A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, • B is a saturated or partially unsaturated monocyclic or bicyclic, heterocyclic group optionally substituted by one or more R 10 groups; * X is selected from SO2, CO2, CO, CONR11 and (CR12 R13) p. Said compounds are capable of inhibiting PAICS and are useful in the treatment of proliferative disorders. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (I).
    本发明的第一个方面涉及式(I)的化合物,或其药学上可接受的盐或酯,• B是一个饱和或部分不饱和的单环或双环,杂环基,可选地由一个或多个R10基团取代;* X从SO2,CO2,CO,CONR11和(CR12R13)p中选择。所述化合物能够抑制PAICS,并且在治疗增生性疾病方面是有用的。进一步方面涉及制药组合物、治疗用途和制备式(I)化合物的过程。
  • ANALYTE DETECTION USING NEAR-INFRARED FLUOROPHORES
    申请人:Portland State University
    公开号:US20160223558A1
    公开(公告)日:2016-08-04
    Embodiments of compounds for selectively detecting an analyte are disclosed, along with methods and kits for detecting analytes with the compounds. The compounds are bridged viologen conjugates including at least one fluorophore according to the general structure At least one of R 1 /R 2 , R 2 /R 3 , R 3 /R 4 , R 5 /R 6 , R 6 /R 7 , and/or R 7 /R 8 together form a substituted or unsubstituted cycloalkyl or aryl.
    公开了用于选择性检测分析物的化合物实施例,以及使用这些化合物检测分析物的方法和试剂盒。这些化合物是包括至少一种荧光团的桥联紫罗兰类化合物,其一般结构如下:至少有R1/R2、R2/R3、R3/R4、R5/R6、R6/R7和/或R7/R8中的至少一对形成取代或未取代的环烷基或芳基。
  • [EN] INHIBITORS OF HEXOKINASE AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS D'HEXOKINASE ET LEURS PROCÉDÉS D'UTILISATION
    申请人:VTV THERAPEUTICS LLC
    公开号:WO2018009539A1
    公开(公告)日:2018-01-11
    Provided herein are substituted substituted heterocycles useful as inhibitors of the HKII enzyme. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention further provides medical uses of substituted heterocycles, for example, as antitumor agents.
    本文提供了作为HKII酶抑制剂的替代杂环化合物。本发明还提供了本发明化合物的药物组合物。此外,本发明还提供了替代杂环化合物的医药用途,例如作为抗肿瘤剂。
  • NEAR-INFRARED FLUORESCENT DYES WITH LARGE STOKES SHIFTS
    申请人:Strongin Robert Michael
    公开号:US20140120628A1
    公开(公告)日:2014-05-01
    Embodiments of near-infrared (NIR) dyes are disclosed, along with methods and kits for detecting analytes with the NIR dyes. The NIR dyes have a structure according to the general structure At least one of R 1 /R 2 , R 2 /R 3 , R 3 /R 4 , R 5 /R 6 , R 6 /R 7 , and/or R 7 /R 8 together forms a substituted or unsubstituted cycloalkyl or aryl.
    本发明公开了近红外(NIR)染料的实施例,以及用于使用NIR染料检测分析物的方法和试剂盒。 NIR染料具有以下一般结构中的结构: 至少其中之一的R1 / R2,R2 / R3,R3 / R4,R5 / R6,R6 / R7和/或R7 / R8形成被取代或未取代的环烷基或芳基。
查看更多

同类化合物

阿卡地新 咪唑立宾 5'-单磷酸酯 咪唑立宾 [(2R,3S,4R,5R)-5-[4-氨基甲酰-5-[[(3R,4R)-3,4-二羟基-2-氧代-5-膦酰氧基戊基]亚氨基甲基氨基]咪唑-1-基]-3,4-二羟基四氢呋喃-2-基]磷酸二氢甲酯 N-[5-氨基-1-(BETA-D-呋喃核糖基)咪唑-4-羰基]-L-天冬氨酸 5-碘-1-(2’,3’,5’-三-O-乙酰基-beta-D-呋喃核糖基)-咪唑并-4-甲腈 5-甲酰氨基咪唑-4-甲酰胺核苷酸 5-氯-1-[3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]咪唑-4-甲酰胺 5-氨基-4-咪唑甲酰胺核糖甙 5'-三磷酸酯 5-氨基-1-(2-O,3-O,5-O-三乙酰基-beta-D-呋喃核糖基)-1H-咪唑-4-甲酰胺 5-氨基-1-(2,7-二羟基-2-氧代四氢-4H-呋喃并[3,2-d][1,3,2]二氧杂环己膦烷-6-基)-1H-咪唑-4-甲酰胺 5-乙炔基-1-呋喃核糖基咪唑-4-甲酰胺 4-(羧甲基)-1-(beta-D-呋喃核糖基)-1H-咪唑 2-硝基-1-beta-D-呋喃核糖基-1H-咪唑 1-alpha-D-阿拉伯呋喃糖基-2-硝基-1H-咪唑 1-(alpha-D-阿拉伯呋喃糖基)-1H-咪唑-2-胺 (2S)-2-[[5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(膦酰氧基甲基)四氢呋喃-2-基]咪唑-4-羰基]氨基]丁二酸 (2R)-2-环己基-2-羟基-2-苯基乙酸 (1-羟基乙基)-5-甲基-1-beta-呋喃核糖基咪唑 5-amino-1-(β-D-ribofuranosyl)-4-(5-propyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-phenyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-ethyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazole 5-[1-(Dimethylamino)ethylideneamino]-1-[2,3-O-(1-methylethylidene)-β-D-ribofuranosyl]-imidazole-4-carbonitrile 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-4-(3-ureidophenyl)imidazole 5-amino-2-(4-fluorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(3-chlorophenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(4-methoxyphenyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-phenylvinyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-phenyl-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-2-(2-furyl)-1-β-D-ribofuranosylimidazole-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-2-(2-thienyl)-4-carboxamide 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamideoxime hydrochloride acadesine-5’-O-bis(benzoxy-L-alaninyl)phosphate 5-diazonium-1-β-D-ribofuranosyl-1H-imidazole-4-carboxamide 5-amino-1-(3-O-methyl-β-D-ribofuranosyl)imidazole-4-carboxamide 5-amino-1-(3-O-n-butyl-β-D-ribofuranosyl) imidazole-4-carboxamide 5-amino-1-(3-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide 5-amino-1-(2-O-ethyl-β-D-ribofuranosyl)-4-imidazole carboxamide N4-(benzyl) AICAR triphosphate N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleotide N1-<(5''-Phospho-β-D-ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside N1-<(β-D-Ribosyl)formimino>-5-aminoimidazole-4-carboxamide ribonucleoside 2-Benzyl-1-(β-D-ribofuranosyl)imidazol-4,5-dicarboxamid 4-N-[(S)-pyrrolidine-2-carbonyl]amino-1-β-D-ribofuranosylimidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-pentyl-1,2,4-oxadiazol-3-yl)imidazole 5-amino-1-(β-D-ribofuranosyl)-4-(5-heptyl-1,2,4-oxadiazol-3-yl)imidazole acadesine-5’-O-bis(methoxy-L-alaninyl)phosphate 4,5-dichloro-1-(β-D-ribofuranosyl)imidazole